Prostatic length predicts functional outcomes after iodine-125 prostate brachytherapy

Area of Science:

• Urology
• Oncology
• Radiation Oncology

Background:

• Brachytherapy is a common treatment for localized prostate cancer.
• Urinary morbidity is a significant concern for patients undergoing prostate brachytherapy.
• Predictive factors for urinary toxicity are crucial for patient counseling and management.

Purpose of the Study:

• To evaluate the utility of prostatic length as a predictor of urinary morbidity after brachytherapy for prostate cancer.
• To identify factors associated with post-treatment urinary symptoms and retention.

Main Methods:

• A prospective analysis of 214 patients who received brachytherapy for prostate cancer between 2002 and 2008.
• Assessment of urinary morbidity using the International Prostate Symptom Score (IPSS) at 3, 9, and 18 months post-treatment.
• Recording of urinary retention rates requiring catheterization.

Main Results:

• Prostatic length and volume significantly correlated with higher posttreatment IPSS at 3 and 9 months.
• Both prostatic length and volume predicted the development of urinary retention requiring catheterization.
• Pretreatment IPSS predicted posttreatment IPSS, but not retention rates; radiation dose and needle count also predicted early IPSS.

Conclusions:

• Prostatic length is a valuable and practical tool for predicting urinary toxicity after prostate cancer brachytherapy.
• Incorporating prostatic length into pretreatment assessments can help anticipate and manage potential urinary side effects.